866-997-4948(US-Canada Toll Free)

Ovarian Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Jun 2016

Category :

Ovarian Cancer

No. of Pages : 1780 Pages

Ovarian Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Ovarian Cancer - Pipeline Review, H1 2016, provides an overview of the Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer
- The report reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ovarian Cancer therapeutics and enlists all their major and minor projects
- The report assesses Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ovarian Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 13
Ovarian Cancer Overview 14
Therapeutics Development 15
Ovarian Cancer - Therapeutics under Development by Companies 17
Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 39
Ovarian Cancer - Pipeline Products Glance 42
Ovarian Cancer - Products under Development by Companies 46
Ovarian Cancer - Products under Investigation by Universities/Institutes 75
Ovarian Cancer - Companies Involved in Therapeutics Development 79
Ovarian Cancer - Therapeutics Assessment 350
Drug Profiles 450
Ovarian Cancer - Dormant Projects 1673
Ovarian Cancer - Discontinued Products 1705
Ovarian Cancer - Product Development Milestones 1712
Appendix 1727

List of Tables
Number of Products under Development for Ovarian Cancer, H1 2016 67
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H1 2016 68
Number of Products under Development by Companies, H1 2016 70
Number of Products under Development by Companies, H1 2016 (Contd..1) 71
Number of Products under Development by Companies, H1 2016 (Contd..2) 72
Number of Products under Development by Companies, H1 2016 (Contd..3) 73
Number of Products under Development by Companies, H1 2016 (Contd..4) 74
Number of Products under Development by Companies, H1 2016 (Contd..5) 75
Number of Products under Development by Companies, H1 2016 (Contd..6) 76
Number of Products under Development by Companies, H1 2016 (Contd..7) 77
Number of Products under Development by Companies, H1 2016 (Contd..8) 78
Number of Products under Development by Companies, H1 2016 (Contd..9) 79
Number of Products under Development by Companies, H1 2016 (Contd..10) 80
Number of Products under Development by Companies, H1 2016 (Contd..11) 81
Number of Products under Development by Companies, H1 2016 (Contd..12) 82
Number of Products under Development by Companies, H1 2016 (Contd..13) 83
Number of Products under Development by Companies, H1 2016 (Contd..14) 84
Number of Products under Development by Companies, H1 2016 (Contd..15) 85
Number of Products under Development by Companies, H1 2016 (Contd..16) 86
Number of Products under Development by Companies, H1 2016 (Contd..17) 87
Number of Products under Development by Companies, H1 2016 (Contd..18) 88
Number of Products under Development by Companies, H1 2016 (Contd..19) 89
Number of Products under Development by Companies, H1 2016 (Contd..20) 90
Number of Products under Investigation by Universities/Institutes, H1 2016 91
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 92
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 93
Comparative Analysis by Late Stage Development, H1 2016 94
Comparative Analysis by Clinical Stage Development, H1 2016 95
Comparative Analysis by Early Stage Development, H1 2016 96
Comparative Analysis by Unknown Stage Development, H1 2016 97
Products under Development by Companies, H1 2016 98
Products under Development by Companies, H1 2016 (Contd..1) 99
Products under Development by Companies, H1 2016 (Contd..2) 100
Products under Development by Companies, H1 2016 (Contd..3) 101
Products under Development by Companies, H1 2016 (Contd..4) 102
Products under Development by Companies, H1 2016 (Contd..5) 103
Products under Development by Companies, H1 2016 (Contd..6) 104
Products under Development by Companies, H1 2016 (Contd..7) 105
Products under Development by Companies, H1 2016 (Contd..8) 106
Products under Development by Companies, H1 2016 (Contd..9) 107
Products under Development by Companies, H1 2016 (Contd..10) 108
Products under Development by Companies, H1 2016 (Contd..11) 109
Products under Development by Companies, H1 2016 (Contd..12) 110
Products under Development by Companies, H1 2016 (Contd..13) 111
Products under Development by Companies, H1 2016 (Contd..14) 112
Products under Development by Companies, H1 2016 (Contd..15) 113
Products under Development by Companies, H1 2016 (Contd..16) 114
Products under Development by Companies, H1 2016 (Contd..17) 115
Products under Development by Companies, H1 2016 (Contd..18) 116
Products under Development by Companies, H1 2016 (Contd..19) 117
Products under Development by Companies, H1 2016 (Contd..20) 118
Products under Development by Companies, H1 2016 (Contd..21) 119
Products under Development by Companies, H1 2016 (Contd..22) 120
Products under Development by Companies, H1 2016 (Contd..23) 121
Products under Development by Companies, H1 2016 (Contd..24) 122
Products under Development by Companies, H1 2016 (Contd..25) 123
Products under Development by Companies, H1 2016 (Contd..26) 124
Products under Development by Companies, H1 2016 (Contd..27) 125
Products under Development by Companies, H1 2016 (Contd..28) 126
Products under Investigation by Universities/Institutes, H1 2016 127
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 128
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 129
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 130
Ovarian Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016 131
Ovarian Cancer - Pipeline by 4SC AG, H1 2016 132
Ovarian Cancer - Pipeline by AB Science SA, H1 2016 133
Ovarian Cancer - Pipeline by AbbVie Inc., H1 2016 134
Ovarian Cancer - Pipeline by AbGenomics International, Inc., H1 2016 135
Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 136
Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 137
Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016 138
Ovarian Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 139
Ovarian Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016 140
Ovarian Cancer - Pipeline by Advantagene, Inc., H1 2016 141
Ovarian Cancer - Pipeline by Advaxis, Inc., H1 2016 142
Ovarian Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 143
Ovarian Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016 144
Ovarian Cancer - Pipeline by Alchemia Limited, H1 2016 145
Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016 146
Ovarian Cancer - Pipeline by Almac Discovery Limited, H1 2016 147
Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc., H1 2016 148
Ovarian Cancer - Pipeline by Alteogen Inc., H1 2016 149
Ovarian Cancer - Pipeline by Ambrx, Inc., H1 2016 150
Ovarian Cancer - Pipeline by Amgen Inc., H1 2016 151
Ovarian Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016 152
Ovarian Cancer - Pipeline by ANP Technologies, Inc., H1 2016 153
Ovarian Cancer - Pipeline by Antoxis Limited, H1 2016 154
Ovarian Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016 155
Ovarian Cancer - Pipeline by Aphios Corporation, H1 2016 156
Ovarian Cancer - Pipeline by Aposense Ltd., H1 2016 157
Ovarian Cancer - Pipeline by Aprea AB, H1 2016 158
Ovarian Cancer - Pipeline by arGEN-X BV, H1 2016 159
Ovarian Cancer - Pipeline by Armour Therapeutics Inc., H1 2016 160
Ovarian Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016 161
Ovarian Cancer - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 162
Ovarian Cancer - Pipeline by ArQule, Inc., H1 2016 163
Ovarian Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 164
Ovarian Cancer - Pipeline by Arvinas, Inc., H1 2016 165
Ovarian Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H1 2016 166
Ovarian Cancer - Pipeline by Astellas Pharma Inc., H1 2016 167
Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 168
Ovarian Cancer - Pipeline by AstraZeneca Plc, H1 2016 169
Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 170
Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H1 2016 171
Ovarian Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 172
Ovarian Cancer - Pipeline by Avipep Pty Ltd, H1 2016 173
Ovarian Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016 174
Ovarian Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016 175
Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 176
Ovarian Cancer - Pipeline by Bayer AG, H1 2016 177
Ovarian Cancer - Pipeline by BeiGene, Ltd., H1 2016 178
Ovarian Cancer - Pipeline by BioCancell Ltd, H1 2016 179
Ovarian Cancer - Pipeline by BioMoti Limited, H1 2016 180
Ovarian Cancer - Pipeline by BioNTech AG, H1 2016 181
Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2016 182
Ovarian Cancer - Pipeline by Bioo Therapeutics, H1 2016 183
Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 184
Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 185
Ovarian Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 186
Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 187
Ovarian Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016 188
Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016 189
Ovarian Cancer - Pipeline by Cavion LLC, H1 2016 190
Ovarian Cancer - Pipeline by Cellceutix Corporation, H1 2016 191
Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 192
Ovarian Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 193
Ovarian Cancer - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 194
Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2016 195
Ovarian Cancer - Pipeline by Celprogen, Inc., H1 2016 196
Ovarian Cancer - Pipeline by Celsion Corporation, H1 2016 197
Ovarian Cancer - Pipeline by Celyad SA, H1 2016 198
Ovarian Cancer - Pipeline by Ceronco Biosciences, H1 2016 199
Ovarian Cancer - Pipeline by CerRx, Inc., H1 2016 200
Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H1 2016 201
Ovarian Cancer - Pipeline by Chikujee Therapeutics, H1 2016 202
Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016 203
Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H1 2016 204
Ovarian Cancer - Pipeline by CohBar, Inc., H1 2016 205
Ovarian Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016 206
Ovarian Cancer - Pipeline by Commence Bio, Inc., H1 2016 207
Ovarian Cancer - Pipeline by Compliment Corporation, H1 2016 208
Ovarian Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016 209
Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 210
Ovarian Cancer - Pipeline by CritiTech, Inc., H1 2016 211
Ovarian Cancer - Pipeline by CTI BioPharma Corp., H1 2016 212
Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 213
Ovarian Cancer - Pipeline by CytRx Corporation, H1 2016 214
Ovarian Cancer - Pipeline by CZ BioMed Corp, H1 2016 215
Ovarian Cancer - Pipeline by Debiopharm International SA , H1 2016 216
Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 217
Ovarian Cancer - Pipeline by DEKK-TEC, Inc., H1 2016 218
Ovarian Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016 219
Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 220
Ovarian Cancer - Pipeline by EirGenix Inc., H1 2016 221
Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2016 222
Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2016 223
Ovarian Cancer - Pipeline by Endocyte, Inc., H1 2016 224
Ovarian Cancer - Pipeline by EntreChem, S.L., H1 2016 225
Ovarian Cancer - Pipeline by Epigen Biosciences, Inc., H1 2016 226
Ovarian Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 227
Ovarian Cancer - Pipeline by Exelixis, Inc., H1 2016 228
Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 229
Ovarian Cancer - Pipeline by Fate Therapeutics, Inc., H1 2016 230
Ovarian Cancer - Pipeline by Forty Seven Inc., H1 2016 231
Ovarian Cancer - Pipeline by Fujifilm Corporation, H1 2016 232
Ovarian Cancer - Pipeline by Galena Biopharma, Inc., H1 2016 233
Ovarian Cancer - Pipeline by GamaMabs Pharma S.A., H1 2016 234
Ovarian Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2016 235
Ovarian Cancer - Pipeline by Gene Techno Science Co., Ltd., H1 2016 236
Ovarian Cancer - Pipeline by Genelux Corporation, H1 2016 237
Ovarian Cancer - Pipeline by Genentech, Inc., H1 2016 238
Ovarian Cancer - Pipeline by Generex Biotechnology Corporation, H1 2016 239
Ovarian Cancer - Pipeline by Genisphere Inc., H1 2016 240

List of Figures
Number of Products under Development for Ovarian Cancer, H1 2016 67
Number of Products under Development for Ovarian Cancer - Comparative Analysis, H1 2016 68
Number of Products under Development by Companies, H1 2016 69
Number of Products under Investigation by Universities/Institutes, H1 2016 91
Comparative Analysis by Late Stage Development, H1 2016 94
Comparative Analysis by Clinical Stage Development, H1 2016 95
Comparative Analysis by Early Stage Products, H1 2016 96
Assessment by Monotherapy Products, H1 2016 402
Assessment by Combination Products, H1 2016 403
Number of Products by Top 10 Targets, H1 2016 404
Number of Products by Stage and Top 10 Targets, H1 2016 404
Number of Products by Top 10 Mechanism of Actions, H1 2016 442
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 442
Number of Products by Top 10 Routes of Administration, H1 2016 498
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 498
Number of Products by Top 10 Molecule Types, H1 2016 500
Number of Products by Stage and Top 10 Molecule Types, H1 2016 500

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *